New hope for advanced cancer: experimental drug DR30206 enters human testing
NCT ID NCT06132828
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tests a new drug called DR30206 in about 216 adults with advanced or metastatic solid tumors who have no other treatment options. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. Participants will receive the drug and be closely monitored for side effects and tumor response.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED OR METASTATIC SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Shanghai Pulmonary Hospital
RECRUITINGShanghai, Shanghai Municipality, 200433, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug shield nerves from Chemotherapy's side effects?
- Can a Tumor's DNA guide better cancer care for kids?
- Can a new PET tracer reveal a key cancer target?
- Can a smart drug home in on Hard-to-Treat cancers?
- Can a new tracer light up cancer growth?
- Can a Dual-Pronged antibody outsmart advanced cancers?